Axis Wealth Partners LLC Has $280,000 Position in Pfizer Inc. $PFE

Axis Wealth Partners LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the second quarter, Holdings Channel reports. The fund owned 11,553 shares of the biopharmaceutical company’s stock after selling 523 shares during the quarter. Axis Wealth Partners LLC’s holdings in Pfizer were worth $280,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter valued at $28,000. Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the 4th quarter valued at $30,000. Finally, Horizon Financial Services LLC bought a new stake in Pfizer during the 1st quarter valued at $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $24.12 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market cap of $137.14 billion, a price-to-earnings ratio of 12.83, a PEG ratio of 0.78 and a beta of 0.55. The company has a fifty day moving average price of $24.60 and a 200-day moving average price of $24.18.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.